Filana Therapeutics posts Eilat XVIII scientific presentation on simufilam in TSC seizures

Filana Therapeutics, Inc.

FLNA

0.00

Filana Therapeutics published a scientific conference presentation outlining simufilam development for tuberous sclerosis complex-associated seizures.
Program targets filamin A modulation; presentation cites animal-model data showing reduced seizure activity in TSC and focal cortical dysplasia type II models.
Document highlights prior safety database in Alzheimer’s trials, covering more than 1,900 patients across two placebo-controlled studies with no emerging safety signals.
Preliminary Phase 2 proof-of-concept design described for ages 12-50, comparing 100 mg BID vs 200 mg BID with seizure-count reduction as a key endpoint.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.